A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

Abstract Background Approximately 95% of advanced colorectal cancer patients (CRC) have mismatch repair MMR-proficient (MMRp) tumors, which do not respond to PD1 blockade alone. Preclinical studies have shown that combined histone deacetylases (HDAC) and/or DNA methyltransferases (DNMT) inhibition c...

Full description

Bibliographic Details
Main Authors: Marina Baretti, Adrian G. Murphy, Marianna Zahurak, Nicole Gianino, Rose Parkinson, Rosalind Walker, Tamara Y. Lopez-Vidal, Lei Zheng, Gary Rosner, Nita Ahuja, Schalper Kurt, Nilofer S. Azad
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Clinical Epigenetics
Subjects:
Epigenetic drugs
Histone deacetylases inhibitors
DNA methyltransferases inhibitors
Colorectal cancer
Microsatellite proficiency
Immunotherapy
Online Access:https://doi.org/10.1186/s13148-023-01485-x

Internet

https://doi.org/10.1186/s13148-023-01485-x

Similar Items